Cardiovascular Side Effects of Neuraminidase Inhibitors: A Review

DOI

10.2991/978-94-6463-048-0_3How to use a DOI?

Keywords

Neuraminidase Inhibitor; Oseltamivir; Remdesivir; Cardiovascular Adverse Effect

Abstract

Neuraminidase inhibitors are antiviral drugs prescribed especially for influenza types A and B. They inhibit the release of the viral neuraminidase protein, which facilitates viral release from the infected cell to the other host’s cells. There has been an increasing use of these drugs during the COVID-19 pandemic. However, few studies have examined the potential serious side effects on physiological systems, such as the cardiovascular system. This review evaluated the literature on the cardiovascular side effects of neuraminidase inhibitors. Articles from several catalogue databases such as PubMed, Science Direct, and journals published by Nature Publishing Group and BMJ, published in English from January 1, 2011, to July 30, 2021, were included. We found reports of cardiovascular adverse events related to the use of remdesivir, oseltamivir, peramivir, zanamivir, and laninamivir. Case reports of hospitalized COVID-19 patients indicated that the sinus bradycardia and prolonged QTc interval observed in patients were associated with remdesivir use and could be resolved with discontinuation of this neuraminidase inhibitor. Supraventricular tachycardia related to the use of oseltamivir in newborns was also reported. A preclinical study found that a high dose of oseltamivir may have increased cardiac preload and decreased contractility, which led to a decrease in cardiac output. Although rare, serious adverse events such as cardiac arrest or cardiac failure were reported after use of peramivir in the elderly. Other papers reported on the potential for cardiac arrest associated with remdesivir use. Similar cases were documented regarding the cardiovascular side effects of laninamivir that manifested as rare palpitations. The cardiovascular side effects associated with the use of neuraminidase inhibitors may vary depending on the dosage, patient’s age and comorbidity. Despite the efficacy and safety profile of neuraminidase inhibitors, this review highlights a concern about the potential cardiovascular side effects related to the use of these drugs. Prescription of these drugs should be carefully monitored and assessed to anticipate serious adverse events.

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Salsabila Zannuba Kurniawan
AU  - Riana Rahmawati
AU  - Fathiyatul Mudzkiroh
AU  - Muhammad Ariq Naufal Arofiq
AU  - Raden Muhammad Bagus Muliawan
PY  - 2022
DA  - 2022/12/19
TI  - Cardiovascular Side Effects of Neuraminidase Inhibitors: A Review
BT  - Proceedings of the 3rd International Conference on Cardiovascular Diseases (ICCvD 2021)
PB  - Atlantis Press
SP  - 10
EP  - 17
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-048-0_3
DO  - 10.2991/978-94-6463-048-0_3
ID  - Kurniawan2022
ER  -